Why Is 10X GENOMICS INC A (TXG) Stock Down Today?

10X Genomics stock (TXG) fell 10.20% to $72.42 on Friday. The decline followed a series of analyst price target adjustments and recent insider selling activity. The stock opened at $80.43 and traded down to a session low of $71.61 before closing near $72.47.

What Happened

Canaccord raised its price target on 10X Genomics to $100 from $60 while maintaining a Buy rating. Morgan Stanley also raised its price target to $70 from $40. Barclays maintained an Overweight rating and raised its price target to $110. Despite these positive actions, the stock experienced significant selling pressure. The company recently partnered with Fred Hutchinson Cancer Center to utilize single cell and spatial technologies for solid tumor and hematologic malignancies.

What The Data Shows

The stock has a market capitalization of $10.5B and remains unprofitable with a trailing twelve months EPS of -0.59. Revenue declined 4.3% over the same period, and the net margin stands at -12.2%. The stock carries a beta of 1.99 and has a 52-week range of $11.16 to $102.81. Over the last eight sessions, the stock moved down 9.6% from $90.36 to $81.72.

Volume was 1.7M shares, which is 0.5x the three-month daily average. Recent insider activity includes 11 sells totaling $12.2M over the last 90 days, with no buys. Director Suliman Shehnaaz and CEO Saxonov Serge sold shares on September 22, 2026, while CFO Taich Adam sold on September 9, 2026. The most recent filing was on September 24, 2026.

What To Watch

Investors should monitor the stock's reaction to the new price targets from Canaccord, Morgan Stanley, and Barclays. The recent partnership with Fred Hutchinson Cancer Center may provide additional context for future performance.